Physician profile
David Thomas Saxon
NPI 1679924443
$4,183.51
in general payments reported to CMS, 2019-2025
27 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.68 · 2021: $13.21 · 2022: $408 · 2023: $948 · 2024: $1,239 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,744.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $690.34 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $541.75 | 2024-2025 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $521.73 | 2022-2025 | Lifevest |
| United Therapeutics Corporation | $513.76 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| E.R. Squibb & Sons, L.L.C. | $274.11 | 2023-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $226.57 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.10 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $188.19 | 2020-2024 | Watchman Flx |
| Novo Nordisk INC | $139.11 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $136.13 | 2025 | Uptravi, Opsumit |
| Pfizer INC. | $123.51 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.52 | 2024-2025 | Farxiga, Brilinta, Wainua |
| Irhythm Technologies, INC. | $90.15 | 2024 | Zio Xt Patch, Zio Monitor |
| Philips North America LLC | $70.65 | 2023-2025 | (Ck4) Mcot, Ecc Solutions |
| Amgen INC. | $48.40 | 2022-2025 | Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.06 | 2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $45.40 | 2022 | |
| Scpharmaceuticals INC. | $36.06 | 2023-2025 | |
| Stryker Corporation | $33.60 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $30.23 | 2022 | |
| Bridgebio Pharma, INC. | $25.83 | 2025 | Attruby |
| Abbott Laboratories | $25.00 | 2021-2022 | |
| Chiesi USA, INC. | $17.86 | 2025 | Juxtapid |
| Heartflow, INC. | $15.94 | 2025 | |
| Becton, Dickinson and Company | $15.85 | 2025 | |
| Inspire Medical Systems, INC. | $13.59 | 2024 | Inspire |
| Sensible Medical Innovations INC | $8.07 | 2023 | Reds System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Saxon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.